These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32373125)

  • 1. Biomarkers for Allogeneic HCT Outcomes.
    Adom D; Rowan C; Adeniyan T; Yang J; Paczesny S
    Front Immunol; 2020; 11():673. PubMed ID: 32373125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
    Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
    Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
    Du W; Cao X
    Front Immunol; 2018; 9():2979. PubMed ID: 30631325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker.
    Paczesny S
    Br J Haematol; 2021 Mar; 192(6):951-967. PubMed ID: 32039480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant.
    Aziz MD; Shah J; Kapoor U; Dimopoulos C; Anand S; Augustine A; Ayuk F; Chaudhry M; Chen YB; Choe HK; Etra A; Gergoudis S; Hartwell MJ; Hexner EO; Hogan WJ; Kitko CL; Kowalyk S; Kröger N; Merli P; Morales G; Nakamura R; Ordemann R; Pulsipher MA; Qayed M; Reshef R; Rösler W; Schechter T; Schreiner E; Srinagesh H; Wölfl M; Wudhikarn K; Yanik G; Young R; Özbek U; Ferrara JLM; Levine JE
    Leukemia; 2020 Jul; 34(7):1898-1906. PubMed ID: 32020045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
    Hashimoto D; Merad M
    Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
    Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.
    Chen S; Zeiser R
    Front Immunol; 2020; 11():1854. PubMed ID: 33013836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-myeloablative transplants for malignant disease.
    Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
    Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
    Zilberberg J; Feinman R; Korngold R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
    Kline J; Subbiah S; Lazarus HM; van Besien K
    Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma biomarkers in graft-versus-host disease: a new era?
    Paczesny S; Levine JE; Braun TM; Ferrara JL
    Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):33-8. PubMed ID: 19147075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.
    Maloney DG
    Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic biomarkers of allogeneic haematopoietic stem cell transplantation outcome-Brief introduction.
    Mrazek F
    HLA; 2019 Dec; 94 Suppl 2():25-29. PubMed ID: 31729192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?
    Toubai T; Tanaka J; Paczesny S; Shono Y; Reddy P; Imamura M
    Curr Stem Cell Res Ther; 2012 May; 7(3):229-39. PubMed ID: 22023620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
    Shimoni A; Nagler A
    Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.